The utility of rat jejunal permeability for biopharmaceutics classification system

Drug Development and Industrial Pharmacy

Volumn 35, Issue 12, 2009, Pages 1496-1502

  Zakeri Milani, Parvin ^a,b   Valizadeh, Hadi ^a,c   Tajerzadeh, Hosnieh ^d   Islambulchilar, Ziba ^e,f  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biopharmaceutics classification; Dissolution; Permeability; Rat jejunal permeability; Single pass intestinal perfusion; Solubility

Indexed keywords

ATENOLOL; CARBAMAZEPINE; CIMETIDINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IBUPROFEN; KETOPROFEN; METOPROLOL; NAPROXEN; PHENAZONE; PIROXICAM; PROPRANOLOL; RANITIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; MALE; NONHUMAN; RAT;

ALGORITHMS; ANIMALS; BIOPHARMACEUTICS; INTESTINAL ABSORPTION; JEJUNUM; MALE; MODELS, ANIMAL; PERFUSION; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS; RATS, WISTAR; SOLUBILITY;

EID: 71049152016     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903037199     Document Type: Article

References (31)

1. Amidon GL, Lennernas H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12(3):413-420
2. Lennernas H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension. J Pharm Pharmacol, 57(3): 273-285
3. Zakeri-Milani P, Barzegar-Jalali M, Azimi M, Valizadeh H. (2009). Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur J Pharm Biopharm, doi:10.1016/j.ejpb.2009. 04.15.
4. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, et al. (2004). Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm, 1(1):85-96.
5. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. (2006). A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm, 3(6): 631-643
6. Blume HH, Schug BS. (1999). The biopharmaceutics classification system (BCS): Class III drugs-better candidates for BA/BE waiver? Eur J Pharm Sci, 9(2):117-121
7. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. (2002). Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res, 19(7):921-925
8. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. (1999). Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet, 36(3):233-254
9. Hillgren KM, Kato A, Borchardt RT. (1995). In vitro systems for studying intestinal drug absorption. Med Res Rev, 15(2):83-109.
10. Salphati L, Childers K, Pan L, Tsutsui K, Takahashi L. (2001). Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol, 53(7): 1007-1013
11. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, et al. (2007). Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci, 10(3):368-379
12. Zakeri-Milani P, Barzegar-Jalali M, Tajerzadeh H, Azarmi Y, Valizadeh H. (2005). Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal, 39(3-4):624-630
13. Valizadeh H, Zakeri-Milani P, Islambulchilar Z, Tajerzadeh H. (2006). A simple and rapid high-performance liquid chromatography method for determining furosemide, hydrochlorothiazide, and phenol red: Applicability to intestinal permeability studies. J AOAC Int, 89(1):88-93.
14. Zakeri-Milani P, Valizadeh H, Azarmi Y, Barzegar-Jalali M, Tajerzadeh H. (2006). Simultaneous determination of metoprolol, propranolol and phenol red in samples from rat in situ intestinal perfusion studies. DARU, 14(2):102-108
15. Dadashzadeh S, Vali AM, Rezagholi N. (2002). LC determination of piroxicam in human plasma. J Pharm Biomed Anal, 28(6):1201-1204
16. Modamio P, Lastra CF, Marino EL. (1998). Error structure for the HPLC analysis for atenolol, metoprolol and propranolol: A useful weighting method in parameter estimation. J Pharm Biomed Anal, 17(3):507-513
17. Swenson ES, Milisen WB, Curatolo W. (1994). Intestinal permeability enhancement: Efficacy, acute local toxicity, and reversibility. Pharm Res, 11(8):1132-1142
18. Welling PG, Selen A, Pearson JG, Kwok F, Rogge MC, Ifan A, et al. (1985). A pharmacokinetic comparison of cephalexin and cefadroxil using HPLC assay procedures. Biopharm Drug Dispos, 6(2):147-157
19. Phillips CA, Michniak BB. (1995). Transdermal delivery of drugs with differing lipophilicities using azone analogs as dermal penetration enhancers. J Pharm Sci, 84(12):1427-1433
20. Sinko PJ, Hu P, Waclawski AP, Patel NR. (1995). Oral absorption of anti-AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations. J Pharm Sci, 84(8):959-965
21. Svensson US, Sandstrom R, Carlborg O, Lennernas H, Ashton M. (1999). High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. Drug Metab Dispos, 27(2):227-232
22. Ernest D, Alfert E, Brenda M, Cross BM, McWilliam AAE. (1993). CCAC, guide to the care and use of experimental animals. Can Counc Anim Care, 1:1-150.
23. Komiya I, Park JY, Kamani A, Ho NFH, Higuchi WI. (1980). Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int J Pharm, 4:249-262
24. Levitt MD, Kneip JM, Levitt DG. (1988). Use of laminar flow and unstirred layer models to predict intestinal absorption in the rat. J Clin Invest, 81(5):1365-1369
25. Rinaki E, Valsami G, Macheras P. (2003). Quantitative biopharmaceutics classification system: The central role of dose/ solubility ratio. Pharm Res, 20(12):1917-1925
26. Varma MV, Khandavilli S, Ashokraj Y, Jain A, Dhanikula A, Sood A, et al. (2004). Biopharmaceutic classification system: A scientific framework for pharmacokinetic optimization in drug research. Curr Drug Metab, 5(5): 375-388
27. Yu LX. (1999). An integrated model for determining causes of poor oral drug absorption. Pharm Res, 16(12):1883-1887
28. Hwang KK, Martin NE, Jiang L, Zhu C. (2003). Permeation prediction of M100240 using the parallel artificial membrane permeability assay. J Pharm Pharm Sci, 6(3):315-320
29. Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, et al. (2004). Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E 100. Drug Dev Ind Pharm, 30(3): 303-317
30. Valizadeh H, Zakeri-Milani P, Barzegar-Jalali M, Mohammadi G, Danesh-Bahreini MA, Adibkia K, et al. (2007). Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev Ind Pharm, 33(1):45-56.
31. Yu LX, Amidon GL. (1998). Characterization of small intestinal transit time distribution in humans. Int J Pharm, 171(2):157-163